Abstract
Therapy for human leukemia is currently limited by toxicity of chemoradiotherapy to normal bone marrow stem cells. This limitation can be circumvented by the prior removal and subsequent reinfusion of autologous bone marrow [1, 2]. In order for successful engraftment to occur, reinfused bone marrow must be pruged of leukemic cells ex vivo while the viability of stem cells remains intact. Monoclonal antibodies have the potential of providing this selective destructive effect.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
